BackEagle Pharmaceuticals Overview

Eagle Pharmaceuticals Other Current Assets

Track Eagle Pharmaceuticals's other current assets ($3.8M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Current Assets
$3.82M
73.22% YoYΔ $-10.44M vs prior year quarter

Peer average / median

Loading

Eagle Pharmaceuticals Other Current Assets History

Loading

Eagle Pharmaceuticals vs. peers: Other Current Assets Comparison

Loading

Eagle Pharmaceuticals Other Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Eagle Pharmaceuticals (EGRX) FAQ

Eagle Pharmaceuticals (EGRX) currently reports a other current assets of $3.8M as of June 2023. That compares with $14M in the prior-year period — down 73.2% year over year. Use the charts on this page to explore Eagle Pharmaceuticals's other current assets history and peer comparisons.

Eagle Pharmaceuticals's other current assets decreased from $14M to $3.8M — a 73.2% year-over-year decrease (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Eagle Pharmaceuticals reported $3.8M in other current assets as of June 2023. That compares with $14M in the prior-year period — down 73.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current assets of $3.8M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Eagle Pharmaceuticals, and consider following EGRX for alerts when major investors trade the stock.

Eagle Pharmaceuticals is classified in the Healthcare sector. On other current assets, it currently shows $3.8M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing EGRX with unrelated industries.